

THE CLAIMS

1 1. (Previously Presented) A method for controlling chronic inflammation in an
2 individual having Metabolic Syndrome, comprising:

3 administering to said individual an effective dosage of a pharmaceutical composition
4 selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate
5 Subfraction, and a combination thereof.

1 2. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by
2 at least one of elevated C-Reactive Protein and elevated serum fibrinogen.

1 3. (Previously Presented) The method of claim 1, wherein the chronic inflammation is
2 evidenced by at least one of elevated platelet count and elevated platelet activity.

1 4. (Original) The method of claim 1, wherein the individual has at least one condition
2 selected from the group consisting of hypertension, hypercholesterolemia, hypertriglyceridemia,
3 and obesity.

1 5. (Canceled)

1 6. (Previously Presented) The method of claim 1, wherein the individual has at least one
2 condition selected from the group consisting of obesity, insulin resistance, hypertension,

dyslipidemia, impaired glucose tolerance, accompanied by increased acute phase proteins including C-Reactive Protein and fibrinogen.

7. (Original) The method of claim 1, wherein said individual has diabetes mellitus, coronary artery disease or cancer.

8. (Withdrawn) A method for controlling elevated blood glucose level in an individual with inflammation-related metabolic disturbances, comprising:

administering to said individual an effective dosage of a composition selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a combination thereof.

9. (Withdrawn) The method of claim 8, wherein the individual has at least one component of the Metabolic Syndrome.

10. (Withdrawn) A method for preventing chronic inflammation due to the presence of or potential exposure to a pathogen, environmental particulates, or environmental toxins, said method comprising: administering to said individual an effective dosage of a pharmaceutical composition selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, and a combination thereof.

11. (Withdrawn) A method for mitigating a symptom in a patient, said symptom characteristic of chronic inflammation, said patient presenting said symptom, said method

3 comprising administering to the patient a pharmaceutical preparation containing an effective
4 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 12. (Withdrawn) The method of claim 11, wherein said patient has at least one
2 component of the Metabolic Syndrome.

1 13. (Withdrawn) The method of claim 12, wherein said symptom is at least one selected
2 from the group consisting of elevated blood pressure, atherogenic dyslipidemia, abdominal
3 obesity, insulin resistance with or without glucose intolerance, a proinflammatory state, and a
4 prothrombotic state.

1 14. (Withdrawn) A method for mitigating a symptom in a patient, said symptom
2 characteristic of an inflammation-related metabolic disturbance, said patient presenting said
3 symptom, said method comprising administering to the patient a pharmaceutical preparation
4 containing an effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte
5 Dialysate Subfraction, or a combination thereof.

1 15. (Withdrawn) The method of claim 14, wherein said patient has at least one
2 component of the Metabolic Syndrome.

1 16. (Withdrawn) The method of claim 15, wherein said component is at least one
2 selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,

3 abdominal obesity, insulin resistance with or without glucose intolerance, a proinflammatory
4 state, and a prothrombotic state.

1 17. (Withdrawn) A method for deferring the progression of a patient from the Metabolic
2 Syndrome including Hypertension, to Diabetes Mellitus, Coronary Heart Disease, or Cancer,
3 said method comprising administering to the patient a pharmaceutical preparation containing an
4 effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate
5 Subfraction, or a combination thereof.

1 18. (Withdrawn) A method for preventing or mitigating development of inflammation-
2 related sequelae of exposure of a person to liquids or vapors containing organic solvents or
3 hydrocarbon fuels, or to environmental toxins capable of provoking chronic inflammation, said
4 method comprising:

5 (a) administering to the person a pharmaceutical preparation containing an effective
6 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
7 combination thereof;

8 (b) monitoring the person for immune function response, inflammation, and blood
9 glucose level; and

10 (c) continuing to administer to the patient said pharmaceutical preparation until the
11 person shows a normal immune function response and normal measures of inflammatory
12 parameters.